Why is Novo Nordisk crashing after data for next-gen weight loss drug?

Novo Nordisk (NVO) plunged to a 52-week low on Friday after the Danish drugmaker released Phase 3 results for its next-gen weight loss therapy, CagriSema, as data gave a pause for its investors, betting on an increasingly competitive market.

While